Sairiv Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 18.75%
- Profit Growth 69.09%
- Ebitda 58.73%
- Net Worth 199.46%
- Total Assets -20.44%
About Sairiv Pharmaceuticals
Sairiv Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 December 2017 (Seven years and two months 9 days old ). Its registered office is in Tiruvallur, Tamil Nadu, India.
The Corporate was formerly known as Sunriv Pharmaceuticals Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Srinivasan Rangarajaan and Veeraraghavan Subharangarajan serve as directors at the Company.
Company Details
-
Location
Tiruvallur, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999TN2017PTC119856
-
Company No.
119856
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Dec 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Sairiv Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srinivasan Rangarajaan
|
Director | 06-Dec-2017 | Current |
|
Veeraraghavan Subharangarajan
|
Director | 29-Mar-2023 | Current |
Financial Performance of Sairiv Pharmaceuticals.
Sairiv Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.75% increase. The company also saw a substantial improvement in profitability, with a 69.09% increase in profit. The company's net worth Soared by an impressive increase of 199.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sairiv Pharmaceuticals?
In 2023, Sairiv Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Simhar Carton Fabrication Private LimitedSrinivasan Rangarajaan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sairiv Pharmaceuticals?
Unlock and access historical data on people associated with Sairiv Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sairiv Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sairiv Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
